جستجوی استاد راهنمای دانشگاهی

Nashwa Masnoon is a Postdoctoral Research Fellow in Geriatric Pharmacotherapy at the Kolling Institute, part of the Faculty of Medicine and Health at the University of Sydney. She is also a hospital pharmacist at the Royal North Shore Hospital. Her academic background includes a BPharm(Hons) and a PhD from the University of South Australia, where her doctoral work focused on identifying risks of adverse outcomes from polypharmacy in older adults with multimorbidity. Dr Masnoon’s research interests span geriatric pharmacology, deprescribing practices, pharmacoepidemiology, and quality use of medicines. Her current projects include developing stewardship programs for anticholinergic/sedative deprescribing, optimizing medication use in hospitals for older patients, and educating hospital pharmacists using the Drug Burden Index intervention bundle. She has co-supervised Honours students in 2022 and 2023, focusing on deprescribing in hospital settings and patient-reported experiences post-intervention. Research Themes: Healthy Ageing Key Approaches: Systematic reviews, clinical interventions, pharmacoepidemiological analysis Dr Masnoon has received notable awards including the 2023 FMH Showcase Travel Award, Royal North Shore Hospital Travel Fellowship (2023), and a 2017 People’s Choice Award for her 3 Minute Thesis presentation. Her work emphasizes improving medication outcomes through evidence-based deprescribing and precision medicine approaches. She is affiliated with the Australasian Pharmaceutical Science Association (APSA), International Pharmaceutical Federation (FIP), and Australian Deprescribing Network (ADeN). Her grants include the 2024 electronic frailty index project and a 2022 travel award-funded initiative.

• Geriatric Pharmacology
• Deprescribing
• Pharmacoepidemiology
• +۳ مورد دیگر

Anne Holland is Professor of Physiotherapy and Head of Respiratory Research at Monash University and Alfred Health in Melbourne, Australia. She is an NHMRC Leadership Fellow (2021–2025) and a Chief Investigator for the NHMRC Centre of Research Excellence in Pulmonary Fibrosis and the NHMRC Centre of Research Excellence in Treatable Traits. Her research focuses on supportive therapies for chronic respiratory diseases, particularly COPD and pulmonary fibrosis, with a strong emphasis on pulmonary rehabilitation, telerehabilitation, and ambulatory oxygen therapy. Her research interests include: Respiratory physiotherapy Pulmonary rehabilitation (home-based and low-cost models) Access to care for chronic lung disease Telerehabilitation and digital health Symptom management in interstitial lung disease Exercise training and physical activity promotion Her recent publications focus on symptom management, digital self-management tools, treatable traits models, and clinical trials in pulmonary fibrosis and COPD. The body of work reflects a strong trend toward patient-centered, accessible, and evidence-based interventions that improve quality of life and clinical outcomes in chronic respiratory conditions. Her major scientific awards include: Society Medal, Thoracic Society of Australia and New Zealand (2021) European Respiratory Society Gold Medal for Allied Health Professionals (2022) NHMRC Investigator Fellow (Leadership 1) (2021) Fellow, Thoracic Society of Australia and New Zealand (2019) American Thoracic Society Pulmonary Rehabilitation Assembly Award (2016) Anne Holland supervises PhD students and is actively involved in advising and grant leadership. She is the Primary Chief Investigator on major trials such as the PERFORM trial and the TAPPET trial, and she leads a multinational ambulatory oxygen trial for fibrotic lung disease. Her work is supported by NHMRC and international collaborations. She is also President of the Thoracic Society of Australia and New Zealand, reflecting her leadership in the field. Anne leads the Holland Respiratory Care Research Group at Monash, which focuses on innovative models of care delivery, validation of remote monitoring tools, and improving patient self-management in chronic lung disease. The team collaborates widely across Australia and internationally, particularly in trials involving pulmonary rehabilitation and treatable traits.

• Respiratory Physiotherapy
• Pulmonary Rehabilitation
• COPD
• +۷ مورد دیگر

Professor Rachel Gibson is a Professor and Head of School in the Allied Health Administration at the University of Adelaide. Her work focuses on gastrointestinal toxicity, chemotherapy-induced adverse effects, and microbiome interactions with diet and health. She leads research in mucositis management, drug delivery systems, and nutritional pathways in oncology care. Her research interests include the gut microbiome's role in chemotherapy toxicity, mechanisms of gastrointestinal damage, and translational applications of intestine-on-chip models. She has contributed to international clinical guidelines on mucositis assessment and palliative care innovations during the pandemic. Publications span 2016-2025, emphasizing chemotherapy-induced diarrhea, microbiome-drug interactions, and dietary interventions. She has pioneered digital health solutions for nutrition support and explored genetic predictors of adverse drug reactions. Current efforts address pain management in pediatric cerebral palsy and optimizing supportive cancer care pathways. Grants and collaborations involve multidisciplinary teams in oncology, bioengineering, and public health. She advises on translational research bridging basic science to clinical practice, with a focus on improving patient outcomes through personalized interventions.

• Gastroenterology
• Oncology
• Nutrition Science
• +۳ مورد دیگر

Dr. Nicole Mifsud is a Senior Research Fellow and Group Leader of the Clinical Immunology Laboratory at Monash University's Department of Biochemistry & Molecular Biology and the Monash Biomedicine Discovery Institute. She holds a PhD in Immunology (University of Melbourne, 2005), specializing in transplantation immunology. Her research focuses on T cell-mediated immune responses, particularly T cell cross-reactivity in human disorders like autoimmunity, drug allergy, and transplant rejection. She explores mechanisms underlying TCR/peptide/HLA interactions and their role in translational medicine and immunotherapeutics. Education: PhD in Immunology, University of Melbourne (2005) Honours (H1), Immunology, University of Melbourne (2000) Bachelor of Biological Sciences, La Trobe University (1992) Research interests include transplantation immunology, viral immunity, and T cell cross-reactivity. Her work contributes to UN Sustainable Development Goals related to health and well-being. Notable collaborations span institutions like the Ludwig Institute for Cancer Research, The Alfred Hospital, and international partners such as Leiden University Medical Centre. Awards include the NHMRC Peter Doherty Training Fellowship (2007) and Best Oral Presentation Awards (2001, 2002). She leads projects funded by NHMRC and Monash University, focusing on alloreactive T cell targets and immunopeptidome studies. Her lab actively collaborates in drug hypersensitivity research and immunotherapy development. Lab members include PhD students and alumni contributing to projects on T cell cross-reactivity and immunotherapy targets. The Mifsud Lab is part of the Immunity Program at Monash BDI, emphasizing translational research for clinical outcomes.

• Transplantation Immunology
• T Cell Cross-Reactivity
• Viral Immunity
• +۳ مورد دیگر

Lisa Kalisch Ellett is an Associate Professor at the University of South Australia, where she works at the Quality Use of Medicines and Pharmacy Research Centre. Her research focuses on improving medication use and health outcomes for Australians, with particular emphasis on studying adverse events associated with medicines. Professor Kalisch Ellett's research interests span several critical areas in pharmacy and medication safety. Her work examines quality use of medicines, adverse drug reactions, pharmacovigilance systems, and medication safety issues particularly affecting vulnerable populations such as older adults and people with dementia. She has conducted significant research on medicine shortages in Australia, including recent studies on ADHD medication shortages. Her work also explores polypharmacy issues, antipsychotic medication use in aged care, and innovative approaches to medication safety monitoring through digital health technologies. Analysis of Professor Kalisch Ellett's recent publications reveals a strong focus on practical applications of pharmacy research to improve real-world medication outcomes. Her work spans multiple methodologies including observational studies, database analyses, and consumer-focused research. Key trends in her research include examining medication safety in vulnerable populations, developing better systems for adverse drug reaction reporting, and addressing medication-related challenges in dementia care. Her research often has direct policy implications for improving medication use in the Australian healthcare system. President of the Australasian Pharmaceutical Science Association Member of the Pharmaceutical Society of Australia Professor Kalisch Ellett serves as president of the Australasian Pharmaceutical Science Association and is a member of the Pharmaceutical Society of Australia, indicating her active engagement with professional organizations in her field. While specific details about her advising and grant activities are limited in the available information, her extensive publication record suggests active research supervision and grant-funded projects. As a researcher at the Quality Use of Medicines and Pharmacy Research Centre, Professor Kalisch Ellett contributes to a collaborative research environment focused on optimizing medication use across various healthcare settings. Her work bridges clinical pharmacy practice with population health approaches to medication safety.

• Quality Use of Medicines
• Pharmacy Research
• Adverse Drug Reactions
• +۷ مورد دیگر

Professor Andrew McLachlan is the Head of School and Dean of Pharmacy at the Sydney Pharmacy School, University of Sydney. He holds a BPharm(Hons1 Medal) and PhD, and is a Member of the Order of Australia (AM). His research focuses on clinical pharmacology, particularly optimizing medication use in special populations such as older adults, children, and critically ill patients. He has led initiatives like the NHMRC Centre for Research Excellence in Medicines and Ageing, and his work emphasizes translating clinical evidence into real-world practice. Education: Bachelor of Pharmacy (First Class Honours) PhD in Clinical Pharmacology Research Interests: Variability in drug response across populations Quality use of medicines in geriatrics Pharmacotherapy optimization in critical care Deprescribing strategies for older adults Grants & Projects: PROSPER Trial (2025): Evaluating opioid alternatives for postoperative pain DREAM Trial (2024): Duloxetine for chronic sciatica Awards: Member of the Order of Australia (AM) Key Contributions: Leading deprescribing initiatives Advancing personalized pharmacotherapy Improving medication safety in vulnerable populations

• Clinical Pharmacology
• Quality Use of Medicines
• Geriatric Pharmacology
• +۳ مورد دیگر

Dr Christine Staatz is an Associate Professor at the University of Queensland 's School of Pharmacy and Pharmaceutical Sciences , specializing in Quality Use of Medicine and Pharmacometrics . Her career spans both clinical pharmacy practice and academic research, with international experience at the University of Glasgow and Uppsala University. B.Pharm (Hons I), University of Queensland (1996) PhD, University of Queensland (2002) Pharmacist registration: Australia (1997), UK (2003) Her research focuses on individualized drug therapy for transplant recipients and critically ill patients, particularly optimizing immunosuppressants (tacrolimus, mycophenolate) and antibiotics (beta-lactams, gentamicin). Recent publications examine age-related pharmacokinetics and microsampling techniques to reduce patient burden. Key contributions include 15+ peer-reviewed articles in 2024-2025 addressing: Bayesian forecasting of drug exposure Free vs total plasma drug concentrations Time-dependent clearance in pediatric chemotherapy Immune-related adverse effects in transplant recipients NHMRC Neil Hamilton Fairley Fellowship (2004) Lions Medical Research Fellowship National grants exceeding AUD$2 million With 14+ completed PhD/MPhil supervisees and ongoing projects in autoimmune diseases and hematopoietic transplantation , she actively mentors students in clinical pharmacology and drug monitoring research.

• Quality Use of Medicine
• Pharmacometrics
• Transplant Pharmacology
• +۳ مورد دیگر

Connie Van is a Senior Lecturer at the University of Sydney's School of Pharmacy, with expertise in medication management, chronic kidney disease, adverse drug reactions, and interprofessional collaboration. Her research bridges clinical practice and healthcare systems, with a focus on optimizing care for vulnerable populations such as pediatric cancer patients, dialysis patients, and critically injured children. Education: BPharm(Hons), PhD, Grad Cert Ed Stud (Higher Ed), Fellow of the Higher Education Academy (FHEA). Key research interests include: Medication safety and adverse drug reaction reporting Pharmacist-physician collaboration in primary care Sick day management protocols for chronic kidney disease Pediatric trauma psychosocial support Emergency nursing frameworks (e.g., HIRAID) Recent work emphasizes translational research, including a cluster-randomized trial for CKD screening and a pharmacy-led intervention study. Over 40 publications since 2007 reflect her multidisciplinary approach across nephrology, oncology, and emergency medicine. Notable grants include funding from the Department of Health and Aged Care for kidney disease quality initiatives, and multiple University of Sydney grants for projects like adverse drug reaction reporting tools and pharmacology education innovation. Current research student: Mimi Truong (project on sick day medication management in kidney disease).

• Medication Management
• Kidney Disease
• Adverse Drug Reactions
• +۴ مورد دیگر

Professor Danijela Gnjidic is affiliated with the Sydney Pharmacy School at the University of Sydney , serving as Interim Deputy Associate Dean of Research in the Faculty of Medicine and Health . She leads the Clinical Practice Guideline for Deprescribing Opioid Analgesics and is a member of the Charles Perkins Centre . Education : PhD (University of Sydney, 2010), MPH (concurrent with PhD), BSc (Hons) International Collaborations : Ghent University (Belgium), Karolinska Institute (Sweden), University of Kentucky and Yale University (USA) Research Focus : Her work spans Geriatric Pharmacology , Deprescribing , Pharmacoepidemiology , and Quality Use of Medicines , with specific emphasis on: Dementia and Medication Management Frailty Assessment in Older Adults Opioid Safety and Chronic Pain Drug Burden Index and Polypharmacy Clinical Guidelines for Deprescribing Healthcare Implementation Strategies Recent Publications analyze trends in opioid deprescribing , frailty measurement , adverse drug reactions , and technology-driven medication management , reflecting interdisciplinary approaches combining geriatrics , epidemiology , and health informatics . Awards include the Thompson Fellowship (2023) , NHMRC Dementia Leadership Fellowship (2017-21) , and multiple accolades for mentorship and leadership in Geriatric Pharmacology . Teaching & Supervision : Coordinates Honours Unit of Study in Pharmacotherapeutics , Public Health , and Evidence-Based Medicine . Supervises projects on dementia care and medication optimization . Associations : Past President of ASCEPT , Deputy Chair of HDR Examinations Subcommittee , and editorial roles for British Journal of Clinical Pharmacology and PLOS One .

• Geriatric Pharmacology
• Quality Use of Medicines
• Pharmacoepidemiology
• +۱ مورد دیگر

Steven Walker is an Associate Professor in the Department of Experiential Development and Graduate Education at Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. His roles include Intern Programs Manager, overseeing units such as PHR5061 and PHR5162, and academic lead for undergraduate units like PHR2042 and PHR3042. His expertise spans clinical pharmacy, education research, and interprofessional collaboration, with a focus on therapeutic reasoning, competency-based education, and work-integrated learning. Education Background: Walker holds a Doctorate by Research (Pharmacy and Pharmaceutical Sciences Education) from Monash (2019) and a Bachelor of Pharmacy (Honours) from the same institution (2010). Research Interests: His work bridges education and practice, addressing therapeutic reasoning models, interprofessional education, and pharmacy practice innovations like antibiotic allergy management and febrile neutropenia treatment. He has contributed to national initiatives such as the Australian Pharmacy Council's Workplace-Based Assessment training and the Society of Hospital Pharmacists Australia's Education Pharmacist framework. Notable Achievements: Recognized with multiple teaching awards, including the Monash Student Association Faculty Teaching Excellence Award (2019, 2020), and the 2022 Citation for Outstanding Contribution to Student Learning. His research has informed curriculum design and assessment methods in digital health and interprofessional collaboration. Collaborations: Active in national and international networks, including collaborations with the Australian Pharmacy Council and SHPA. His projects include framing postgraduate digital health curricula and advancing workplace-based training programs.

• Therapeutic Reasoning
• Interprofessional Education
• Competency-Based Education
• +۵ مورد دیگر

Dr. Yet Hong Khor is an Associate Professor (Research) in Immunology at Monash University, with clinical appointments at Alfred Health and Austin Health. She is a dual-trained Respiratory and Sleep Physician and an emerging leader in interstitial lung disease (ILD) and oxygen therapy research, ranked in the top 0.1% globally in ILD research by Expertscape. Education: PhD in Interstitial Lung Disease and Oxygen Therapy, University of Melbourne (2019) Bachelor of Medicine/Bachelor of Surgery (1st Class Honours), University of Tasmania (2007) Bachelor of Medical Science (Honours) in Respiratory Medicine, University of Tasmania (2005) Her research focuses on risk prediction , disease management , and quality improvement in ILD and oxygen therapy, with the ultimate goal of early diagnosis and improved treatment pathways for pulmonary fibrosis. Her work integrates clinical innovation, patient-centered outcomes, and translational research. Her recent publications reflect a strong emphasis on clinical guidelines, drug-induced lung disease, telemedicine in ILD, and patient-reported outcomes. Themes include risk modeling, treatment adherence, and innovative care delivery models such as telehealth and nurse-led services. Scientific Awards: NHMRC Emerging Leadership Fellowship Australian Endeavour Executive Leadership Award (2019) Austin Medical Research Foundation Bernie Sweet Clinical Research Fellowship (2021) American Thoracic Society International Conference Awards (2019, 2021) Australasian Rare Lung Disease Conference Best Poster Award (2021) Lizotte Family Grant-in-Aid for Idiopathic Pulmonary Fibrosis Dr. Khor actively supervises physicians in training, Honours, Masters, and HDR students, with mentorship leading to conference presentations and publications. She holds leadership roles in national and international research projects, including investigator-initiated ILD programs and telemedicine models. She also contributes extensively to academic service, serving on organizing committees for major respiratory conferences and as Associate Editor for journals including Respirology Case Reports and European Respiratory Journal . She leads the Austin Health Oxygen Service and is a key specialist in ILD services at both Austin and Alfred Health, integrating clinical leadership with research innovation.

• Interstitial Lung Disease
• Pulmonary Fibrosis
• Oxygen Therapy
• +۷ مورد دیگر

Dr. G R Letchuman Ramanathan is a Professor of Medicine at the Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia since May 2021. Previously, he served as Senior Consultant Physician and Endocrinologist at Hospital Ipoh and National Head of the Ministry of Health Internal Medicine Services. He specializes in diabetes therapeutics, endemic goitre, health system research, and patient safety. His academic journey includes a MBBS from the University of Malaya (1981–1986) and a Master of Medicine from Universiti Kebangsaan Malaysia (1990–1994). His research focuses on diabetes epidemiology, patient safety, and health system improvements. Notable contributions include studies on allopurinol-induced drug reactions and barriers to research in government hospitals. He has led projects such as the 'Health effects of heat in Southeast Asia' and clinical trials for chronic kidney disease treatments. Dr. Ramanathan is also the President of the College of Physicians, Malaysia. His work contributes to UN Sustainable Development Goals related to health and well-being (SDG 3) and quality education (SDG 4). Key Awards: Fellow of Academy of Medicine, Malaysia Grants/Projects: Health effects of heat in Southeast Asia (2023–2027) Randomized trial on BI 690517 efficacy in kidney disease (2022–2023)

• Diabetes therapeutics & epidemiology
• Endemic Goitre
• Health System Research
• +۳ مورد دیگر

Dr. Alison SHIELD is an Associate Professor in the School of Pharmacy at the University of Canberra. With a PhD in genetic toxicology from Flinders University, she has held postdoctoral positions at the Mayo Clinic and Australian National University before joining UC in 2008. Education: PhD (Flinders University), BBiotech (Hons) (Flinders University) Her research focuses on pharmacology, toxicology, and pharmacogenetics, with recent work on pharmacokinetic education, medication safety, and physical activity interventions in culturally and linguistically diverse (CALD) communities. She has supervised multiple projects including Medication safety and Charcot Marie Tooth disease and Increasing physical activity levels in women of childbearing age . Selected scientific awards include NHMRC Postdoctoral Research Fellow. Her teaching interests emphasize integrating basic sciences into clinical education, supported by a Graduate Certificate in Higher Education.

• Pharmacology
• Toxicology
• Pharmacogenetics
• +۵ مورد دیگر

Dr. Choon Siew Eng is an Associate Professor at Monash University Malaysia's Jeffrey Cheah School of Medicine and Health Sciences and a senior consultant dermatologist at Hospital Sultanah Aminah in Johor Bahru, Malaysia. She holds a MBBS from the University of Malaya (1982) and is a Fellow of the Royal College of Physicians, London (2003). Her postgraduate training included dermatology specialization at St. John’s Institute of Dermatology, London. Dr. Choon’s research focuses on chronic inflammatory skin diseases, particularly psoriasis (including pustular psoriasis), atopic dermatitis, hidradenitis suppurativa, and cutaneous adverse drug reactions. She has contributed to global consensus guidelines for generalized pustular psoriasis (GPP), including treatment goals and diagnostic criteria. Her work aligns with UN Sustainable Development Goals targeting health and well-being (SDG 3). Recent research highlights include spesolimab’s efficacy in reducing GPP inflammation and safety across clinical trials, as well as epidemiological studies on GPP prevalence in multiethnic populations. She serves on editorial boards (Experimental Dermatology) and international organizations (International Psoriasis Council, Malaysian Skin Foundation). Dr. Choon actively collaborates globally, particularly in Asia-Pacific regions, to advance understanding of psoriasis subtypes and adverse drug reactions. Her work bridges clinical practice, research, and public health, emphasizing patient-centered care for rare and severe skin conditions.

• Psoriasis
• Atopic Dermatitis
• Hidradenitis Suppurativa
• +۳ مورد دیگر

Dr. Muhammad Shahid Javaid is a postdoctoral research fellow in the Department of Neuroscience at the School of Translational Medicine, Monash University. He completed his PhD from Monash University and has presented his research on national and international platforms. His research focuses on: Development of precision medicines using human stem cell-based in vitro epilepsy models Biological reprogramming of patients' blood cells into stem cells Converting stem cells into brain cells, neurons, and 3D brain organoids Creating personalized 'disease-in-a-dish' models for patients with medically intractable epilepsy Bioinformatics-based computer-aided medicine design His recent publications demonstrate expertise in integrating in vitro human iPSCs-derived neuron and in vivo animal approaches for anti-seizure compound screening, developing human in vitro models of epilepsy using stem cells, conducting molecular docking studies for redox balance regulation in epilepsy, analyzing sex differences in adverse drug reactions from antiseizure medications, and performing in silico analysis of stem cell differentiation mechanisms. His awards include: Gold Medal (2016) Monash Graduate Scholarship (MGS) (2018) Monash International Tuition Scholarship (MITS) (2018) Dr. Javaid has been actively involved in research projects related to patient-specific disease models for Homer1 gene mutations, pre-clinical evaluation of adenosine A1 receptor modulators for drug-resistant epilepsy, intracerebral delivery of Neuropeptide Y for epilepsy treatment, and drug screening using patient-specific iPSCs-derived neurons. He also served as an Authorised Officer and Public Health Officer at the Department of Health (Victoria) from February 2021 to June 2022, demonstrating his commitment to public health applications of his research.

• Neuroscience
• Stem cell research
• Precision Medicine
• +۷ مورد دیگر